Project Grant R01HL173734
Award Date
7/15/24
Completion Date
6/30/28
Dollars Obligated
$399K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award, issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), totals $813,042 and will be performed from July 2024 to June 2027. The grant aims to develop an innovative causal machine learning platform to predict and mitigate hematologic adverse events, such as thrombosis and bleeding, in patients with myeloid malignancies. The key products and services to be delivered under this award...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant in the amount of $173,609 to The Washington University to develop and evaluate an Artificial Intelligence-driven Clinical Decision Support (CDS) system for perioperative blood management. The grant is funded under the Cardiovascular Diseases Research CFDA Program 93.837. The goal of the proposed research is to create and assess the feasibility and preliminary effectiveness of a personalized CDS tool, named S-PATH, that...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 Project Grant (R01HL177813) to Case Western Reserve University (CWRU) to develop and validate a novel "Transfer Volume Regression" method to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The 4-year project aims to create a smart, standardized,...
This National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program Project Grant award of $169,222 to the University of Alabama at Birmingham (UAB) aims to identify and evaluate ancestry and sex-related pharmacogenomic and metabolomic signatures that influence the response to oral anticoagulants (OACs), including warfarin and direct oral anticoagulants (DOACs). The research will focus on characterizing predictors of OAC pharmacokinetics, pharmacodynamics, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,129.23 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis. The grant supports a late-stage implementation research strategy to evaluate the effectiveness of a heart failure (HF) polypill treatment approach in India compared to usual care. The polypill combines guideline-directed medical therapies including a beta-blocker, angiotensin receptor blocker, and...
This $815,510 Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop a genetic-based classifier that can predict cancer patients' susceptibility to drug-induced cardiovascular toxicity. The University of Chicago, the prime awardee, will use a novel system of cardiac guided differentiation cultures and single-cell RNA sequencing to study the effects of three anticancer drugs...
This $114,375 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to improve the ability to identify cardiovascular disease (CVD) patients treated with statins or antiplatelet therapy at increased risk for adverse drug responses and adverse outcomes. The project will utilize data from the All of Us Research Program to: Evaluate statin prescribing patterns, adverse drug responses, and adverse outcomes...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to New York University School of Medicine, totaling $198,936.00 with a start date of August 5, 2024 and an ultimate completion date of July 31, 2029. The grant will fund research to quantify the effects of restrictive drug coverage policies for guideline-recommended heart failure medications on provider prescribing, patient adherence, and clinical...
This federal Project Grant award of $777,674.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effectiveness of guideline-directed medical therapies for patients with heart failure and mid-range ejection fraction. The award will fund the development of natural language processing...
This federal Project Grant award of $540,771 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a personalized, socially aware, and equitable stroke risk prediction tool for patients with atrial fibrillation (AF). The key objectives are: (1) to discover new clinical and socioeconomic factors that influence stroke risk in AF patients, (2) to build novel machine learning-based models that incorporate social...